Dan Leonard
Stock Analyst at UBS
(4.03)
# 565
Out of 5,124 analysts
308
Total ratings
56.32%
Success rate
9.59%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $147.60 | +21.95% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $19.31 | -27.50% | 7 | Nov 7, 2025 | |
| TECH Bio-Techne | Maintains: Buy | $65 → $70 | $65.28 | +7.23% | 12 | Nov 6, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $52.67 | -18.36% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $112.33 | -2.07% | 11 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $225 → $250 | $240.53 | +3.94% | 17 | Oct 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $620.72 | -4.95% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $101.65 | -47.86% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $9.57 | +56.74% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $608.89 | -49.91% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $236.59 | -4.90% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,485.15 | -9.10% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $325.50 | -4.76% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $328.45 | -5.62% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $105.05 | +9.47% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $94.10 | +5.21% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $12.27 | +103.75% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $216.11 | -14.40% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $10.02 | -10.18% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $25.99 | +34.67% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $147.11 | +35.95% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $3.88 | +183.51% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $248.74 | -71.86% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $16.11 | -56.55% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $400.54 | -13.87% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $201.48 | +29.05% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $180.46 | -19.65% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $74.91 | +20.14% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $47.01 | +35.40% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $260.40 | +30.57% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $21.59 | +11.16% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $6.52 | +436.81% | 12 | Aug 14, 2019 |
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $147.60
Upside: +21.95%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $19.31
Upside: -27.50%
Bio-Techne
Nov 6, 2025
Maintains: Buy
Price Target: $65 → $70
Current: $65.28
Upside: +7.23%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $52.67
Upside: -18.36%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $112.33
Upside: -2.07%
IQVIA Holdings
Oct 29, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $240.53
Upside: +3.94%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $620.72
Upside: -4.95%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $101.65
Upside: -47.86%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $9.57
Upside: +56.74%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $608.89
Upside: -49.91%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $236.59
Upside: -4.90%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,485.15
Upside: -9.10%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $325.50
Upside: -4.76%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $328.45
Upside: -5.62%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $105.05
Upside: +9.47%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $94.10
Upside: +5.21%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $12.27
Upside: +103.75%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $216.11
Upside: -14.40%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $10.02
Upside: -10.18%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $25.99
Upside: +34.67%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $147.11
Upside: +35.95%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $3.88
Upside: +183.51%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $248.74
Upside: -71.86%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $16.11
Upside: -56.55%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $400.54
Upside: -13.87%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $201.48
Upside: +29.05%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $180.46
Upside: -19.65%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $74.91
Upside: +20.14%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $47.01
Upside: +35.40%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $260.40
Upside: +30.57%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $21.59
Upside: +11.16%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $6.52
Upside: +436.81%